
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom reported a robust 22% year-over-year growth in international revenue and a 21% increase in domestic revenue, highlighting its successful penetration into the Type 2 diabetes (T2D) market and burgeoning international markets like France and Canada. The company's upward revisions in sales guidance to $4.630B-$4.650B, reflecting a projected 15% year-over-year growth, underscore its strong performance and expected continued momentum from Medicare expansion and additional coverage wins. Furthermore, key innovations and a focus on remote monitoring are anticipated to enhance growth potential, reinforcing a favorable long-term outlook for the company's financial performance.
Bears say
DexCom's revised profitability outlook and a decline in gross margins signal potential challenges ahead, with adjusted EBIT and EBITDA expectations facing downward revisions. The company reported its first non-record new patient quarter in a significant timeframe, raising concerns about the impact of quality issues on business performance amidst increasing competition and integration of competitor products such as the Libre. Additionally, the forecasted growth rates for sensor revenue have been downgraded, reflecting anticipated pressures from both competitive dynamics and operational challenges, including increased scrap rates and rising operating expenses.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares